FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016627210> ?p ?o ?g. }

• W3016627210 endingPage "1417" @default.
• W3016627210 startingPage "1411" @default.
• W3016627210 abstract "Abstract Purpose The aim of this study was to investigate the outcomes of a fixed intravitreal aflibercept regimen in patients with vascular pigment epithelium detachment (vPED) secondary to age-related macular degeneration with refractory subretinal fluid. Methods A prospective, interventional case series involved 20 eyes of 20 patients with refractory subretinal fluid and vPED treated with at least three injections of intravitreal anti-VEGF prior to study inclusion. After study inclusion, patients were treated with three injections of intravitreal aflibercept 2 mg/0.05 mL monthly followed by injections every 8 weeks. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) were evaluated at all visits. Fluorescein angiography and indocyanine green angiography were performed at baseline and quarterly. Primary outcomes were effectivity of a fixed treatment as measured in change in BCVA, PED greatest linear diameter (GLD), and PED height from baseline to month 12. In an additional post hoc analysis, vPED patients were differentiated into two groups: (1) vPED lesions that showed persistence of subretinal fluid throughout 1 year of treatment and (2) vPED lesions that showed complete resolution of subretinal fluid at least at one of the monthly performed OCT volume scans. Reflectivity values were determined in the subretinal pigment epithelium (RPE) compartment in OCT scans at baseline, month 6 and 12. Results A total of 18 patients completed the study protocol. The mean age was 74.8 ± 10.6 years, and six patients were female. The median BCVA of all patients was 72.0 ± 8.0 EDTRS letters at baseline and 72.5 ± 9.5 EDTRS letters at 12-month follow-up ( p = 0.7420). The median PED height in all patients as measured in the OCT images significantly decreased from 372.0 ± 140.0 μm to 149.0 ± 142.0 μm after 12 months of treatment ( p = 0.0020). Persistent subretinal fluid was present at every OCT control in six patients (group 1). Twelve patients showed resolution of subretinal fluid at least at one OCT control (group 2). Reflectivity values in the sub-RPE compartment in OCT scans were 41.48 ± 4.48 (group 1) and 42.62 ± 12.34 (group 2) at baseline ( p = 0.854) and 65.88 ± 6.74 and 50.87 ± 14.11 at month 12 ( p = 0.038). Conclusions Intravitreal aflibercept in refractory vPED leads to a significant reduction in PED height and disease activity as well as preservation of BCVA over 1 year. Persistent subretinal fluid was present in PED lesions with high values of reflectivity under the RPE, suggesting both a diffusion barrier and an increasing fibrovascular maturization of the choroidal neovascularization. Trial registration ClinicalTrials.gov Identifier: NCT03370380" @default.
• W3016627210 created "2020-04-24" @default.
• W3016627210 creator A5000714876 @default.
• W3016627210 creator A5037018029 @default.
• W3016627210 creator A5052060292 @default.
• W3016627210 creator A5054137638 @default.
• W3016627210 creator A5075925349 @default.
• W3016627210 creator A5083355438 @default.
• W3016627210 creator A5085629103 @default.
• W3016627210 date "2020-04-18" @default.
• W3016627210 modified "2023-09-27" @default.
• W3016627210 title "Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography" @default.
• W3016627210 cites W1967830128 @default.
• W3016627210 cites W1976540988 @default.
• W3016627210 cites W2004117352 @default.
• W3016627210 cites W2015795623 @default.
• W3016627210 cites W2053255808 @default.
• W3016627210 cites W2059550937 @default.
• W3016627210 cites W2075978545 @default.
• W3016627210 cites W2083043469 @default.
• W3016627210 cites W2116942242 @default.
• W3016627210 cites W2119635054 @default.
• W3016627210 cites W2151876190 @default.
• W3016627210 cites W2216501909 @default.
• W3016627210 cites W2225799082 @default.
• W3016627210 cites W2314609576 @default.
• W3016627210 cites W2331906989 @default.
• W3016627210 cites W2768385301 @default.
• W3016627210 cites W2792105216 @default.
• W3016627210 cites W2965769306 @default.
• W3016627210 cites W2971436863 @default.
• W3016627210 cites W3025821417 @default.
• W3016627210 doi "https://doi.org/10.1007/s00417-020-04675-y" @default.
• W3016627210 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7306025" @default.
• W3016627210 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32306096" @default.
• W3016627210 hasPublicationYear "2020" @default.
• W3016627210 type Work @default.
• W3016627210 sameAs 3016627210 @default.
• W3016627210 citedByCount "7" @default.
• W3016627210 countsByYear W30166272102020 @default.
• W3016627210 countsByYear W30166272102021 @default.
• W3016627210 countsByYear W30166272102022 @default.
• W3016627210 countsByYear W30166272102023 @default.
• W3016627210 crossrefType "journal-article" @default.
• W3016627210 hasAuthorship W3016627210A5000714876 @default.
• W3016627210 hasAuthorship W3016627210A5037018029 @default.
• W3016627210 hasAuthorship W3016627210A5052060292 @default.
• W3016627210 hasAuthorship W3016627210A5054137638 @default.
• W3016627210 hasAuthorship W3016627210A5075925349 @default.
• W3016627210 hasAuthorship W3016627210A5083355438 @default.
• W3016627210 hasAuthorship W3016627210A5085629103 @default.
• W3016627210 hasBestOaLocation W30166272101 @default.
• W3016627210 hasConcept C118487528 @default.
• W3016627210 hasConcept C141071460 @default.
• W3016627210 hasConcept C188816634 @default.
• W3016627210 hasConcept C2776403814 @default.
• W3016627210 hasConcept C2776694085 @default.
• W3016627210 hasConcept C2777802072 @default.
• W3016627210 hasConcept C2778024200 @default.
• W3016627210 hasConcept C2778257484 @default.
• W3016627210 hasConcept C2778749236 @default.
• W3016627210 hasConcept C2778818243 @default.
• W3016627210 hasConcept C2780248432 @default.
• W3016627210 hasConcept C2780827179 @default.
• W3016627210 hasConcept C2781065829 @default.
• W3016627210 hasConcept C2781100027 @default.
• W3016627210 hasConcept C71924100 @default.
• W3016627210 hasConceptScore W3016627210C118487528 @default.
• W3016627210 hasConceptScore W3016627210C141071460 @default.
• W3016627210 hasConceptScore W3016627210C188816634 @default.
• W3016627210 hasConceptScore W3016627210C2776403814 @default.
• W3016627210 hasConceptScore W3016627210C2776694085 @default.
• W3016627210 hasConceptScore W3016627210C2777802072 @default.
• W3016627210 hasConceptScore W3016627210C2778024200 @default.
• W3016627210 hasConceptScore W3016627210C2778257484 @default.
• W3016627210 hasConceptScore W3016627210C2778749236 @default.
• W3016627210 hasConceptScore W3016627210C2778818243 @default.
• W3016627210 hasConceptScore W3016627210C2780248432 @default.
• W3016627210 hasConceptScore W3016627210C2780827179 @default.
• W3016627210 hasConceptScore W3016627210C2781065829 @default.
• W3016627210 hasConceptScore W3016627210C2781100027 @default.
• W3016627210 hasConceptScore W3016627210C71924100 @default.
• W3016627210 hasFunder F4320320303 @default.
• W3016627210 hasIssue "7" @default.
• W3016627210 hasLocation W30166272101 @default.
• W3016627210 hasLocation W30166272102 @default.
• W3016627210 hasLocation W30166272103 @default.
• W3016627210 hasOpenAccess W3016627210 @default.
• W3016627210 hasPrimaryLocation W30166272101 @default.
• W3016627210 hasRelatedWork W2015993450 @default.
• W3016627210 hasRelatedWork W2319930158 @default.
• W3016627210 hasRelatedWork W2320987231 @default.
• W3016627210 hasRelatedWork W2410017589 @default.
• W3016627210 hasRelatedWork W2577052657 @default.
• W3016627210 hasRelatedWork W2577193304 @default.
• W3016627210 hasRelatedWork W2745923716 @default.
• W3016627210 hasRelatedWork W2769959318 @default.
• W3016627210 hasRelatedWork W2783788819 @default.

• next